The United States will reach Independence Day without meeting President Joe Biden’s goal of giving at least one COVID-19 vaccine dose to 70% of adults, a shortfall that arrives as the highly transmissible Delta variant expands and the national vaccination campaign becomes increasingly divided by age and geography.

CDC’s July 2 weekly review says 54.6% of the entire U.S. population had received at least one dose by July 1 and warns that cases are rising in some parts of the country. The agency also highlights low vaccination among people ages 18 to 29 and says unvaccinated people remain at serious risk of infection and transmission.

The missed target does not erase the scale of the vaccination campaign. Hundreds of millions of doses have been administered, deaths and hospitalizations have fallen sharply from winter peaks, and much of daily life has reopened. But the next stage is proving harder than the first: vaccines are abundant, yet the population most willing to receive them has increasingly already done so.

A July 4 goal designed to mark a turning point

Biden announced the 70% adult target in a May 4 fact sheet, pairing it with a goal of fully vaccinating 160 million adults by July 4. The administration described the benchmarks as the next phase in moving the country toward normal social and economic activity.

On June 2, the White House launched a nationwide “Month of Action” to close the remaining gap. The accompanying plan mobilized businesses, community organizations, colleges, faith groups, local leaders and volunteers to encourage vaccination, while expanding walk-in access and community outreach.

Biden said that day in public remarks that nearly 170 million Americans had already received a shot and 52% of adults were fully vaccinated. The administration’s strategy assumed that easier access and targeted persuasion could keep first-dose demand high enough to reach the symbolic July 4 threshold.

Younger adults remain the hardest group to reach

CDC data show why the final portion of the campaign is moving more slowly. A June 25 report on adults ages 18 to 39 found that only 34% reported having been vaccinated during the March-to-May survey period. Nearly one quarter said they probably or definitely would not get vaccinated, while another 23.2% were unsure or said they probably would.

The same analysis found significant differences by age, education, income, insurance status and race. Adults 18 to 24 had lower reported vaccination than those 35 to 39, and adults living outside metropolitan areas were substantially more likely to say they probably or definitely would not be vaccinated.

A separate CDC coverage analysis found similar gaps in the actual national vaccination program. The agency concluded that reaching younger adults would require more than supply: vaccination would have to be brought into workplaces, mobile clinics and other settings while addressing concerns about safety, effectiveness and the perceived need for vaccination.

Delta raises the cost of leaving gaps

The slowing first-dose pace matters because the virus is changing. Delta, first identified in India, is more transmissible than earlier strains and is becoming an increasingly important share of U.S. infections. Federal health officials have warned that communities with lower vaccination coverage could remain vulnerable even as highly vaccinated areas experience fewer severe outcomes.

The risk is particularly clear because vaccination now extends well beyond older adults. FDA expanded Pfizer-BioNTech’s emergency authorization in May to include adolescents ages 12 through 15, a decision recorded in the agency’s contemporaneous COVID-19 update. That expansion opened vaccination to millions more people before summer activities and the coming school year.

CDC’s Advisory Committee on Immunization Practices has continued to examine vaccine safety and benefit as use expands among younger populations. Its June 23 meeting materials show the committee weighing rare myocarditis reports against the much larger expected reductions in COVID-19 cases, hospitalizations and other severe outcomes.

The campaign shifts from mass delivery to persuasion

The United States solved much of its early vaccine problem through manufacturing contracts, federal distribution, pharmacies and mass vaccination sites. The constraint is now less about whether doses exist than whether people want them and can be reached efficiently.

That changes the public-health strategy. Large sites that could vaccinate thousands of people a day are less useful when demand is scattered. Health officials increasingly need physicians, community clinics, employers and trusted local organizations to reach smaller groups whose decisions depend on personal concerns or local circumstances.

The CDC’s July 2 review makes clear that national averages can obscure local vulnerability. A country in which more than half the population has received at least one dose can still contain communities where vaccination remains low enough for sustained outbreaks, especially if a more transmissible variant arrives.

The July 4 goal was intended to provide a simple measure of collective progress. Missing it by a modest margin does not reverse the dramatic improvement of the past six months, but it does reveal the challenge ahead. The easiest vaccinations have largely been given. The remaining work will require more individualized outreach, more attention to geographic and demographic gaps and a sustained argument that vaccination remains worthwhile even as the country feels increasingly normal.

With Delta expanding, that argument is becoming more urgent rather than less. The country has moved from a race to manufacture and distribute vaccine to a race between vaccination and a variant that can exploit the places where protection remains thin.